289 related articles for article (PubMed ID: 23935856)
1. T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer.
Monteiro AC; Leal AC; Gonçalves-Silva T; Mercadante AC; Kestelman F; Chaves SB; Azevedo RB; Monteiro JP; Bonomo A
PLoS One; 2013; 8(7):e68171. PubMed ID: 23935856
[TBL] [Abstract][Full Text] [Related]
2. Cooperation between T and B cells reinforce the establishment of bone metastases in a mouse model of breast cancer.
Monteiro AC; de Andrade Garcia D; Du Rocher B; Fontão APGA; Nogueira LP; Fidalgo G; Colaço MV; Bonomo A
Bone; 2024 Jan; 178():116932. PubMed ID: 37832903
[TBL] [Abstract][Full Text] [Related]
3. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis.
Canon JR; Roudier M; Bryant R; Morony S; Stolina M; Kostenuik PJ; Dougall WC
Clin Exp Metastasis; 2008; 25(2):119-29. PubMed ID: 18064531
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumption.
Monteiro AC; Bonomo A
Bone; 2021 Feb; 143():115755. PubMed ID: 33217627
[TBL] [Abstract][Full Text] [Related]
6. CD8
Monteiro AC; Bonomo A
Bone; 2021 Sep; 150():116014. PubMed ID: 34022456
[TBL] [Abstract][Full Text] [Related]
7. Plumbagin inhibits osteoclastogenesis and reduces human breast cancer-induced osteolytic bone metastasis in mice through suppression of RANKL signaling.
Sung B; Oyajobi B; Aggarwal BB
Mol Cancer Ther; 2012 Feb; 11(2):350-9. PubMed ID: 22090419
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with the RANKL inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin reduces bone lesions and skeletal tumor burden in a model of breast cancer skeletal metastasis.
Holland PM; Miller R; Jones J; Douangpanya H; Piasecki J; Roudier M; Dougall WC
Cancer Biol Ther; 2010 Apr; 9(7):539-50. PubMed ID: 20150760
[TBL] [Abstract][Full Text] [Related]
9. 15-deoxy-δ12,14-prostaglandin j2 inhibits osteolytic breast cancer bone metastasis and estrogen deficiency-induced bone loss.
Kim KR; Kim HJ; Lee SK; Ma GT; Park KK; Chung WY
PLoS One; 2015; 10(4):e0122764. PubMed ID: 25859665
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer metastasis to the bone: mechanisms of bone loss.
Chen YC; Sosnoski DM; Mastro AM
Breast Cancer Res; 2010; 12(6):215. PubMed ID: 21176175
[TBL] [Abstract][Full Text] [Related]
11. Osteoprotegerin in bone metastases: mathematical solution to the puzzle.
Ryser MD; Qu Y; Komarova SV
PLoS Comput Biol; 2012; 8(10):e1002703. PubMed ID: 23093918
[TBL] [Abstract][Full Text] [Related]
12. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
Trinkaus M; Ooi WS; Amir E; Popovic S; Kalina M; Kahn H; Singh G; Gainford MC; Clemons M
Oncol Rep; 2009 May; 21(5):1153-9. PubMed ID: 19360288
[TBL] [Abstract][Full Text] [Related]
13. RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro.
Casimiro S; Mohammad KS; Pires R; Tato-Costa J; Alho I; Teixeira R; Carvalho A; Ribeiro S; Lipton A; Guise TA; Costa L
PLoS One; 2013; 8(5):e63153. PubMed ID: 23696795
[TBL] [Abstract][Full Text] [Related]
14. Plumbagin inhibits breast tumor bone metastasis and osteolysis by modulating the tumor-bone microenvironment.
Li Z; Xiao J; Wu X; Li W; Yang Z; Xie J; Xu L; Cai X; Lin Z; Guo W; Luo J; Liu M
Curr Mol Med; 2012 Sep; 12(8):967-81. PubMed ID: 22574935
[TBL] [Abstract][Full Text] [Related]
15. IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells.
McCoy EM; Hong H; Pruitt HC; Feng X
BMC Cancer; 2013 Jan; 13():16. PubMed ID: 23311882
[TBL] [Abstract][Full Text] [Related]
16. Involvement of cell-cell and cell-matrix interactions in bone destruction induced by metastatic MDA-MB-231 human breast cancer cells in nude mice.
Nakamura H; Hiraga T; Ninomiya T; Hosoya A; Fujisaki N; Yoneda T; Ozawa H
J Bone Miner Metab; 2008; 26(6):642-7. PubMed ID: 18979165
[TBL] [Abstract][Full Text] [Related]
17. Tumor-supportive and osteoclastogenic changes induced by breast cancer-derived factors are reversed by inhibition of {gamma}-secretase.
Fong JE; Le Nihouannen D; Komarova SV
J Biol Chem; 2010 Oct; 285(41):31427-34. PubMed ID: 20679341
[TBL] [Abstract][Full Text] [Related]
18. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
19. RANKL inhibition blocks osteolytic lesions and reduces skeletal tumor burden in models of non-small-cell lung cancer bone metastases.
Miller RE; Jones JC; Tometsko M; Blake ML; Dougall WC
J Thorac Oncol; 2014 Mar; 9(3):345-54. PubMed ID: 24496001
[TBL] [Abstract][Full Text] [Related]
20. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts.
Jun AY; Kim HJ; Park KK; Son KH; Lee DH; Woo MH; Chung WY
Invest New Drugs; 2014 Feb; 32(1):1-13. PubMed ID: 23673814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
